NANETS (North American Neuroendocrine Tumor Society) Symposium

34th Annual Congress of the European Association of Nuclear Medicine (EANM)

ESMO (European Society for Medical Oncology) Congress

Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

American Society of Clinical Oncology (ASCO) Annual Meeting

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

Advanced Accelerator Applications to Build Targeted RadioLigand Therapy Production Facility in Indianapolis

Advanced Accelerator Applications Announces Health Canada Approval of NETSPOT® Diagnostic Imaging Agent Kit to Detect Neuroendocrine Tumours

Advanced Accelerator Applications Announces Start of Phase III Study Investigating Radioligand Therapy Lutathera® as First-Line Treatment in Patients with Advanced GEP-NETs